Doctors Back New Skin Cancer Vaccine From Moderna
Top doctors praise new cancer vaccine trial data from Moderna and Merck after strong patient recovery numbers.
Skin cancer patients have a new reason to hope. Top doctors call a new shot from Moderna and Merck a major step forward.
The treatment combines Moderna's mRNA tool with Merck's cancer drug Keytruda. Patients take it after surgery. Six cancer specialists reviewed the clinical trial results. They found that the shot helps keep melanoma from returning.
Wall Street traders reacted with caution. Stock prices stayed flat after the announcement. Still, doctors see a bright path ahead. They believe this method can train the body to fight other tumors too.
Medical progress often moves ahead of the market. This drug combo shows how mRNA science can change routine health care. Patients and investors should track the next steps closely.
Source: CNBC
More from Biotech
